NCT05746208 2026-03-17Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine TumorsUniversity of California, San FranciscoPhase 2 Recruiting29 enrolled
NCT03950609 2026-01-09Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid TumorsM.D. Anderson Cancer CenterPhase 2 Active not recruiting36 enrolled